Umbilical cord mesenchymal stem cell therapy - Alliancells Bioscience

Drug Profile

Umbilical cord mesenchymal stem cell therapy - Alliancells Bioscience

Alternative Names: UC-MSC - Alliancells Bioscience

Latest Information Update: 16 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alliancells Bioscience
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Liver cirrhosis; Rheumatoid arthritis

Most Recent Events

  • 16 Feb 2016 No development reported - Phase-I/II for Cirrhosis in China (IV)
  • 14 Apr 2015 No development reported - Phase-I/II for Rheumatoid arthritis in China (IV)
  • 01 Jul 2014 Phase-I/II clinical trials in Cirrhosis in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top